<DOC>
	<DOC>NCT02719197</DOC>
	<brief_summary>The primary purpose of this first-in-man study is to investigate whether a new drug for neurological disorders is safe and well-tolerated when administered orally to healthy male adults</brief_summary>
	<brief_title>First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders</brief_title>
	<detailed_description />
	<mesh_term>Nervous System Diseases</mesh_term>
	<criteria>Signed informed consent Healthy on the basis of physical examination, electrocardiogram and laboratory tests. A subject who has a female partner of childbearing potential or a pregnant partner agrees to use a condom in combination with spermicide or a condom, respectively, from screening, during the entire study, and for at least 3 months after (the last) study drug intake Body mass index (BMI) of 18.0 to 29.9 kg/m2 (inclusive) at screening and Day 1. Systolic blood pressure (SBP) 100140 mmHg, diastolic blood pressure (DBP) 5090 mmHg, and pulse rate 5090 bpm (inclusive), measured after 5 min in the supine position at screening and at Day 1. History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the study treatment Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions Any cardiac condition or illness with a potential to increase the cardiac risk of the subject based on medical history, physical examination, or electrocardiogram (ECG) evaluations Any circumstances or conditions, which, in the opinion of the Investigator, may affect full participation in the study or compliance with the protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>